Abstract
Letters and Corrections1 April 1981Nifedipine and Raynaud's PhenomenonANDRÉ KAHAN, M.D., SIMON WEBER, M.D., BERNARD AMOR, M.D., LIONEL SAPORTA, M.D., MAURICE HODARA, M.D., MICHEL DEGEORGES, M.D.ANDRÉ KAHAN, M.D.Search for more papers by this author, SIMON WEBER, M.D.Search for more papers by this author, BERNARD AMOR, M.D.Search for more papers by this author, LIONEL SAPORTA, M.D.Search for more papers by this author, MAURICE HODARA, M.D.Search for more papers by this author, MICHEL DEGEORGES, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-94-4-546_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: We read with interest the review "Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders: Part II: Hemodynamic Effects and Clinical Applications" by Stone and associates (1). We wish to emphasize another indication for use of nifedipine.Numerous therapeutic approaches to Raynaud's phenomenon have been used, with various results (2-5). We have evaluated the therapeutic effect of the calcium-channel blocking agent nifedipine in Raynaud's phenomenon. In each of the 16 patients included in our study (mean age, 38; 12 female, four male) digital vasospasm could be reproduced within 3 minutes by immersion of both hands in...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
